Radiation enhancement by 9-aminocamptothecin: The effect of fractionation and timing of administration

International Journal of Radiation Oncology Biology Physics

Volumn 44, Issue 3, 1999, Pages 659-664

  Kirichenko, Alexander V ^a   Rich, Tyvin A ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Camptothecins; Chronomodulated; Circadian; Irradiation; Mouse mammary carcinoma; Radiation sensitization

Indexed keywords

9 AMINOCAMPTOTHECIN; DNA TOPOISOMERASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD TOXICITY; BREAST TUMOR; CIRCADIAN RHYTHM; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; INTRAMUSCULAR DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RADIATION ENTEROPATHY; RADIOSENSITIZATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; CIRCADIAN RHYTHM; COMBINED MODALITY THERAPY; DRUG ADMINISTRATION SCHEDULE; FEMALE; INJECTIONS, INTRAMUSCULAR; MAMMARY NEOPLASMS, ANIMAL; MICE; MICE, INBRED C3H; RADIATION-SENSITIZING AGENTS; SPECIFIC PATHOGEN-FREE ORGANISMS;

EID: 0033002539     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(99)00062-0     Document Type: Article

References (23)

1. Lamond J., Wang M., Kinsella T., Boothman D. Radiation lethality enhancement with 9-amino camptothecin Comparison to other topoisomerase 1 inhibitors . Int J Radiat Onc Biol Phys. 36:(2):1996;369-376.
2. Kirichenko A.V., Rich T.A., Newman R.A., Travis E.L. Potentiation of murine MCA-4 carcinoma radioresponse by 9-amino20 (S)-camptothecin. Cancer Res. 57:1997;1929-1933.
3. Pommier Y. DNA Topoisomerase I and II in cancer chemotherapy Update and perspectives . Cancer Chemother Pharmacol. 32:1993;103-108.
4. Boothmann D.A., Fukunada N., Wang M. Down-regulation of Topoisomerase 1 in mammalian cells following ionizing radiation. Cancer Res. 54:1994;4618-4626.
5. Nelson W.G., Kastan M.B. DNA strand breaks of the DNA template alterations that trigger p53-dependent DNA damage response pathways. Mol Cell Biol. 14:1994;1815-1823.
6. Del Bino G., Bruno S., Yi P.N., Darzynkiewicz Z. Apoptotic cell death triggered by camptothecin or teniposide. The cell cycle specificity and effects of ionizing radiation. Cell Prolif. 25:1992;537-548.
7. Falk S.J., Smith P.J. DNA damaging and cell cycle effects of the topoisomerase 1 poison camptothecin in irradiated human cells. Int J Radiat Biol. 61:(6):1992;749-757.
8. Milas L., Hunter N., Mason K., Withers H.R. Immunological resistance to pulmonary metastasis in C3HHf/Bu mice bearing syngeneic fibrosarcoma of different sizes. Cancer Res. 34:1974;61-71.
9. Lamond J.P., Wang M., Kinsella T.J., Boothman D.A. Concentration and timing dependency of lethality enhancement between Topotecan, a Topoisomerase I inhibitor, and ionizing radiation. Int J Radiat Biol. 36:1996;361-368.
10. Covey J.M., Jaxel C., Kohn K.W., Pommier Y. Protein-linked DNA strand breaks induced in mammalian cell by camptothecin, an inhibitor of topoisomerase I. Cancer Res. 49:1989;5016-5022.
11. Houghton PJ, Stewart CF, Zamboni WC, Thompson J, Luo X, Danks M, Houghton JA. Schedule-dependent efficacy of camptothecin in models of human cancer. The camptothecins from discovery to the patient. In: Proceedings of the New York Academy of Sciences. New York, New York; 1996:Abstr. 188.
12. Hochster H, Liebes L, Sorich J; et al. Increasing cleavable complex formation in peripheral blood lymphocytes with increasing topotecan infusion duration - Rationale for prolonged administration of camptothecins. Proceedings of the Sixth Conference on Topoisomerases in Therapy. Amsterdam 1995:Abstr. 88.
13. Kudoh S., Kurihara N., Okishio K., Hirata J., Yoshikawa J., Masuda N., Takada M., Takeda K., Negoro S., Fukuoka M. A phase I/II study of weekly irinotecan (CPT-11) and simultaneous thoracic radiotherapy for unresectable locally advanced non-small cell lung cancer. Proc ASCO. 15:1996;372.
14. Saltz L., Early E., Kelsen D., Kemeny N., Schwartz G.K., Ilson D., Fleishauer A., Semple D., Spriggs D. Phase I study of chronic daily low-dose irinotecan. Proc ASCO. 18:1997;463.
15. Rothenberg ML. Current status of irinotecan (CPT-11) in the United States: The camptothecins from discovery to the patient. In: Proceedings of the New York Academy of Sciences. New York, New York; 1996:Abstr. 272.
16. Sheving L.E., Sheving L.A., McClellan J.L., Feners R.J. Experimental basis for circadian cancer chemotherapy. J Infus Chemother. 5:(N1):1995;3-7.
17. Filipski E., Levi F., Vardot N., Li X.M., Mormont C., Lemaigre G., Mahjoubi M. Circadian changes in irinotecan toxicity in mice. Proc AACR. 38:1997;305.
18. Ohdo S., Makinosumi T., Ishizaki T., Yukawa E., Higuchi S., Nakano S., Ogawa N. Cell cycle-dependent chronotoxicity of irinotecan hydrochloride. J Pharm Exp Therap. 283:1997;1383-1388.
19. Thames H., Ruifrok A., Mason K. The effect of proliferative status and clonogen content on the response of jejunal crypts to split-dose irradiation. Radiat Res. 147:1997;172-179.
20. Takasuna K., Hagiwara T., Hirohashi M., Kato M., Nomura M., Nagai E., Yokoi T., Kamataki T. Involvement of B-Glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats. Cancer Res. 56:1996;3752-3757.
21. De W., Marsh R., Chu N.-M., Vauthey J.-N., Mendenhall W.M., Lauwers G.Y., Bewsher C., Copeland E.M. Preoperative treatment of patients with locally advanced unresectable rectal adenocarcinoma utilizing continuous chronobiologically shaped 5-fluorouracil infusion and radiation therapy. Cancer. 78:1996;217-225.
22. Weinstein G.D., Rich T.A., Shumate C.R., et al. Preoperative infusional Chemoradiation and surgery with or without an electron beam intraoperative boost for advanced primary rectal cancer. Int J Radiat Oncol Biol Phys. 32:1995;197-204.
23. Montembault S., Goldwasser F., Bresault-Bonnet C., Giacchetti S., Tigaud J.M., Metzger G., Jasmin C., Misset J.L., Levi F. A pilot study of CPT-11 chronomodulated delivery in patients with metastatic colorectal carcinoma. Proc AACR. 39:1998;387.